Teva Pharmaceutical Industries Limited (TLV: TEVA)
Israel
· Delayed Price · Currency is ILS · Price in ILA| Market Cap | 69.87B |
| Revenue (ttm) | 62.35B |
| Net Income (ttm) | -3.56B |
| Shares Out | n/a |
| EPS (ttm) | -3.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,219,160 |
| Open | 6,199.00 |
| Previous Close | 6,189.00 |
| Day's Range | 6,050.00 - 6,213.00 |
| 52-Week Range | 3,376.00 - 7,323.00 |
| Beta | 0.88 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2024 |
About TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. ... [Read more]
Financial Performance
In 2023, TEVA's revenue was $15.85 billion, an increase of 6.17% compared to the previous year's $14.93 billion. Losses were -$559.00 million, -77.15% less than in 2022.
Financial numbers in USD Financial StatementsNews
FMR LLC Bolsters Stake in Teva Pharmaceutical Industries Ltd
FMR LLC Bolsters Stake in Teva Pharmaceutical Industries Ltd
Teva to Present at the Jefferies London Healthcare Conference
TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Jeffer...
Market Whales and Their Recent Bets on TEVA Options
Financial giants have made a conspicuous bearish move on Teva Pharmaceutical Indus. Our analysis of options history for Teva Pharmaceutical Indus (NYSE: TEVA) revealed 9 unusual trades. Delving into ...
Teva Pharmaceutical Industries Limited (TEVA) Q3 2024 Earnings Call Transcript
Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript
TEVA earnings call for the period ending September 30, 2024.
Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the consensus of $4.12 billion . Revenues increased 13% year-over-year and 15%...
Teva Pharm CEO says will work productively with Trump administration
Teva Pharmaceutical Industries expects to work productively with the incoming Trump administration in the United States, chief executive Richard Francis said on Wednesday.
Teva's Explosive Q3 Results: Pivot to Growth Strategy Shocks Investors with Record Revenue Surge
Teva's Explosive Q3 Results: Pivot to Growth Strategy Shocks Investors with Record Revenue Surge
Teva Pharmaceutical Industries Limited 2024 Q3 - Results - Earnings Call Presentation
The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with their 2024 Q3 earnings call.
Teva Pharmaceutical Flashes A Buy Signal On Upbeat Third-Quarter Report
Teva stock jumped early Wednesday after the company reported better-than-expected third-quarter sales and profit.
Teva gains after raising outlook for second time this year
Teva Pharmaceutical (TEVA) stock gains in premarket after the company posted better than expected Q3 2024 financials and raised its full-year outlook. Read more here.
Teva Pharmaceutical third-quarter profit, revenue top estimates
Teva Pharmaceutical Industries reported a larger than expected rise in third-quarter profit, boosted by strong sales of copycat medicines and its branded drugs to treat migraines and Huntington's dise...
Teva Pharmaceutical beats Q3 top and bottom line estimates, raises outlook
Teva Pharmaceutical press release (TEVA): Q3 Non-GAAP EPS of $0.69 beats by $0.03. Revenue of $4.3B (+11.7% Y/Y) beats by $170M. Outlook for 2024 Non-GAAP Resul
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
For an accessible version of this Press Release, please visit www.tevapharm.com
Teva Pharmaceutical Q3 2024 Earnings Preview
Teva long-acting olanzapine shows improvements in schizophrenia patients
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patien...
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-‘749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)
Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscience Data show TEV-‘749 drug delivery technology r...
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)
TEL AVIV, Israel & PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new, positiv...
European Commission fines MS drug maker Teva over improper patent use
The European Commission says it has fined the Israeli generic drug maker, Teva, more than €460m for improperly seeking to protect the patent for its multiple sclerosis drug and for disparaging a rival...
Teva fined $500M by European Commission for disparaging rival MS drug
The European Commission has fined Israeli drugmaker Teva (TEVA) $500M for disparaging a rival product to its blockbuster multiple sclerosis drug Copaxone. Read more here.
Commission fines Teva €462.6 million for abuse of patent and disparagement
The pharmaceutical giant has been fined for anticompetitive behaviour designed to exclude generic producers from competing with its blockbuster multiple sclerosis medicine.
Teva Fined Around $500 Million Over MS Drug Competition Concerns
The European Union fined Israel’s Teva Pharmaceutical 462.6 million euros, saying it abused its market position in a way that might have delayed competitors from entering the multiple sclerosis market...
Teva Fined Around $500 Million Over MS Drug Competition Concerns
The European Union fined Israel's Teva Pharmaceutical 462.6 million euros, saying it abused its market position in a way that might have delayed competitors from entering the multiple sclerosis market...
Teva Statement on European Commission Decision; Company to Appeal
TEL AVIV, Israel, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals Industries Ltd. (NYSE: and TASE: TEVA) is responding to the European Decision following its investigation into the company's pr...